文献速递淋巴瘤造血干细胞移植与细胞治疗

CD19-CAR T细胞治疗中枢神经系统淋巴瘤中TIAN的临床表现、管理与结局

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.
PubMed 文献 · Blood · 2025-01-01

该研究对56例接受CD19-CAR T细胞治疗的中枢神经系统淋巴瘤(CNSL)患者进行TIAN综合特征分析,10例(17.9%)发生TIAN,中位发生时间为输注后3.5天。基线CNS肿瘤体积>3.4 cm³可识别TIAN风险(灵敏度87.5%、特异度80.5%),TIAN与更高的总缓解率(90% vs 52%)和改善的无进展生存(HR 0.22)相关。

要点

  • CNSL患者CD19-CAR T治疗后TIAN发生率17.9%(10/56),中位发生时间3.5天。
  • 基线CNS肿瘤体积>3.4 cm³可识别TIAN风险,灵敏度87.5%、特异度80.5%。
  • TIAN与更高总缓解率(90% vs 52%)和改善的无进展生存(HR 0.22)相关。

核心结论

  • TIAN是一种局限的、针对肿瘤的、靶向性神经毒性综合征,与既存CNSL病灶密切相关,且不同于ICANS。
  • 基线CNS肿瘤体积可能有助于识别TIAN风险患者并可能指导管理。

研究设计与样本

  • 对56例接受CD19-CAR T细胞治疗的中枢神经系统淋巴瘤(CNSL)患者进行TIAN的综合特征分析。

主要发现

  • TIAN发生于10/56(17.9%)CNSL患者,临床起病中位时间为CD19-CAR T细胞输注后3.5天(范围1-9天)。
  • TIAN与细胞因子释放综合征的关联频率低于ICANS(60% vs 100%;P = .009)。
  • TIAN症状通常短暂且完全可逆,但1例患者出现致死性结局。
  • 基线较大CNS肿瘤体积可识别TIAN风险患者(曲线下面积0.847;P = .002);最大Youden J统计量确定判别性肿瘤体积阈值为>3.4 cm³,携带87.5%灵敏度和80.5%特异度。
  • TIAN与CD19-CAR T细胞更高的总缓解率相关(90% vs 52%;P = .036),并在多因素Cox比例风险回归中与改善的无进展生存相关(风险比0.22;95%置信区间0.07-0.61;P = .006)。

临床怎么用

  • 原文结论指出基线CNS肿瘤体积可能有助于识别TIAN风险患者并可能指导管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor inflammation-associated neurotoxicity (TIAN) was recently proposed as a unique complication of immunotherapy in patients with brain tumor. Here, we report a first comprehensive characterization of TIAN in patients with central nervous system (CNS) lymphoma (CNSL) treated with CD19-directed chimeric antigen receptor (CD19-CAR) T cells. TIAN occurred in 10 of 56 (17.9%) patients with CNSL, with clinical onset at a median 3.5 days (range, 1-9) after CD19-CAR T-cell infusion. It was less frequently associated with cytokine release syndrome (60% vs 100%; P = .009) than immune effector cell-associated neurotoxicity syndrome (ICANS). Although symptoms were usually transient and fully reversible, TIAN was associated with a fatal outcome in 1 patient. Larger CNS tumor volume at baseline allowed the identification of patients at risk for TIAN (area under the curve, 0.847; P = .002). Maximizing Youden J statistics, a discriminatory tumor volume threshold of >3.4 cm3 was determined, which carried 87.5% sensitivity and 80.5% specificity. TIAN correlated with higher overall response rates to CD19-CAR T cells (90% vs 52%; P = .036) and improved progression-free survival (hazard ratio, 0.22; 95% confidence interval, 0.07-0.61; P = .006) on multivariate Cox proportional hazard regression. Postmortem histopathological evaluation of a TIAN lesion revealed a dense macrophage population with central necrosis and peripheral reactive gliosis, accompanied by loss of white matter and intracytoplasmic myelin in foamy macrophages. Collectively, our work supports TIAN as a localized on-tumor, on-target neurotoxicity syndrome, closely related to preexisting CNSL lesions and distinct from ICANS. CNS tumor volume at baseline may allow to identify patients at risk and may guide management.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kaulen LD, Martinez-Lage M, Abramson JS, et al. Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy. Blood. 2025. PMID: 40663771. doi:10.1182/blood.2025028964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。